Increased Aggregation Response of Platelets in Patients with Inflammatory Bowel Disease

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2006 Feb 28

PMID 16501857

Citations 23

Authors

Akira Andoh

Takashi Yoshida

Yuki Yagi

Shigeki Bamba

Kazunori Hata

Tomoyuki Tsujikawa

Katsuyuki Kitoh

Masaya Sasaki

Yoshihide Fujiyama

Affiliations

Soon will be listed here.

Abstract

Background: Platelets play an important role in hemostatic and inflammatory responses. To evaluate any potential enhancement of platelet activity in patients with inflammatory bowel disease (IBD), we measured the platelet aggregation responses to various stimuli.

Methods: Twenty-two healthy controls, 24 patients with ulcerative colitis (UC) and 25 patients with Crohn's Disease (CD) were studied. The aggregation responses induced by three agonists (epinephrine, collagen, and ADP) were measured by an 8-channel aggregometer. The platelet-derived microparticles (PDMP) levels were measured by an enzyme-linked immunosorbent assay.

Results: Twenty-one out of the 22 healthy controls did not respond to epinephrine (0.1 microg/ml), collagen (0.2 microg/ml), or ADP (1.0 microM). Eight out of the 12 active UC patients were sensitive to all agonists, and 4 patients showed increased sensitivity to epinephrine/collagen or epinephrine/ADP. Three out of the 12 inactive UC patients were normal, but 9 of these patients showed increased sensitivity, mainly to epinephrine. Ten out of the 12 active CD patients were sensitive to all agonists, and 2 active CD patients were sensitive to epinephrine/collagen or epinephrine/ADP. Eight out of the 13 inactive CD patients were sensitive to two or all agonists. Even after remission, almost all of the UC and CD patients showed some increased sensitivity to the agonists. The platelet number and the plasma PDMP levels were significantly higher in the active IBD patients than in the control group.

Conclusions: Platelet aggregation responses are enhanced in IBD, even in inactive-phase patients. This increased sensitivity of the platelets may play an important role in the pathophysiology of IBD.

Citing Articles

Abnormal platelet parameters in inflammatory bowel disease: a systematic review and meta-analysis.

Xu C, Song Z, Hu L, Tong Y, Hu J, Shen H BMC Gastroenterol. 2024; 24(1):214.

PMID: 38961334 PMC: 11221001. DOI: 10.1186/s12876-024-03305-9.

Fecal calprotectin and platelet count predict histologic disease activity in pediatric ulcerative colitis: results from a projection-predictive feature selection.

Schiller B, Wirthgen E, Weber F, Schiller S, Radke M, Classen M Eur J Pediatr. 2024; 183(8):3277-3288.

PMID: 38709314 PMC: 11263432. DOI: 10.1007/s00431-024-05554-y.

Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview.

Gala D, Newsome T, Roberson N, Lee S, Thekkanal M, Shah M Diseases. 2022; 10(4).

PMID: 36278572 PMC: 9589934. DOI: 10.3390/diseases10040073.

Epidemiology and Risk Factors of Portal Venous System Thrombosis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Lin H, Bai Z, Meng F, Wu Y, Luo L, Shukla A Front Med (Lausanne). 2022; 8:744505.

PMID: 35111772 PMC: 8801813. DOI: 10.3389/fmed.2021.744505.

Activation of Platelet NLRP3 Inflammasome in Crohn's Disease.

Zhang G, Chen H, Guo Y, Zhang W, Jiang Q, Zhang S Front Pharmacol. 2021; 12:705325.

PMID: 34262463 PMC: 8273542. DOI: 10.3389/fphar.2021.705325.

References

Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T . Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut. 2004; 53(4):542-8. PMC: 1773996. DOI: 10.1136/gut.2003.025411. View

Perry F, Heller P, Kamiya J, Levine J . Altered autonomic function in patients with arthritis or with chronic myofascial pain. Pain. 1989; 39(1):77-84. DOI: 10.1016/0304-3959(89)90177-2. View

Gemmell C, Sefton M, Yeo E . Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem. 1993; 268(20):14586-9. View

Rachmilewitz D . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298(6666):82-6. PMC: 1835436. DOI: 10.1136/bmj.298.6666.82. View

Fagerstam J, Whiss P, Strom M, Andersson R . Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res. 2000; 49(9):466-72. DOI: 10.1007/s000110050618. View

Yun-Choi H, Park K, Pyo M . Epinephrine induced platelet aggregation in rat platelet-rich plasma. Thromb Res. 2001; 100(6):511-8. DOI: 10.1016/s0049-3848(00)00353-4. View

TALSTAD I, Rootwelt K, GJONE E . Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol. 1973; 8(2):135-8. View

Morris M, Russell A, Kapoor V, Cain M, Elliott J, West M . Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986; 17(2):143-9. DOI: 10.1016/0165-1838(86)90089-5. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

10.

Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y . Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost. 2001; 85(2):326-30. View

11.

Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M . Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol. 2005; 100(9):2042-8. DOI: 10.1111/j.1572-0241.2005.50381.x. View

12.

Packham M, Mustard J . Clinical pharmacology of platelets. Blood. 1977; 50(4):555-73. View

13.

Straub R, Herfarth H, Falk W, Andus T, Scholmerich J . Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease?. J Neuroimmunol. 2002; 126(1-2):116-25. DOI: 10.1016/s0165-5728(02)00047-4. View

14.

Nakajima A, Sendo W, Tsutsumino M, Koseki Y, Ichikawa N, Akama H . Acute sympathetic hyperfunction in overlapping syndromes of systemic lupus erythematosus and polymyositis. J Rheumatol. 1998; 25(8):1638-41. View

15.

Vrij A, Rijken J, Van Wersch J, Stockbrugger R . Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest. 2000; 30(3):188-94. DOI: 10.1046/j.1365-2362.2000.00616.x. View

16.

Collins C, Cahill M, Newland A, Rampton D . Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology. 1994; 106(4):840-5. DOI: 10.1016/0016-5085(94)90741-2. View

17.

VanWijk M, VanBavel E, Sturk A, Nieuwland R . Microparticles in cardiovascular diseases. Cardiovasc Res. 2003; 59(2):277-87. DOI: 10.1016/s0008-6363(03)00367-5. View

18.

Wakefield A, Sawyerr A, Dhillon A, Pittilo R, Rowles P, Lewis A . Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet. 1989; 2(8671):1057-62. DOI: 10.1016/s0140-6736(89)91078-7. View

19.

Quera R, Shanahan F . Thromboembolism--an important manifestation of inflammatory bowel disease. Am J Gastroenterol. 2004; 99(10):1971-3. DOI: 10.1111/j.1572-0241.2004.40923.x. View

20.

Nomura S . Function and clinical significance of platelet-derived microparticles. Int J Hematol. 2002; 74(4):397-404. DOI: 10.1007/BF02982082. View